Hubei Guangji Pharmaceutical (000952.SZ) has obtained the supplementary application approval letter for the tablet product of Valacyclovir Hydrochloride.

Hubei Guangji Pharmaceutical (000952.SZ) announced that recently, the company received the "Drug Supplemental Application Approval Notification Letter" issued by the National Medical Products Administration for the approval of valacyclovir hydrochloride tablets. After review, it was approved to increase the specification of the product by 0.5g (calculated as valacyclovir) and issued the drug approval number. The product passed the generic drug quality and efficacy consistency evaluation. Approval was also granted for changes in the prescription process and quality standards of the product. It is reported that valacyclovir hydrochloride tablets are a national medical insurance category B drug, which can effectively treat herpes zoster and is suitable for treating herpes simplex virus infection and for preventing the recurrence of herpes simplex virus infection.